



Foundation Medicine, Inc.
Investor Relations Department
150 Second Street
Cambridge, MA 02141
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FMI


Last Trade:	41.10
Trade Time:	4:00 PM ET October 20, 2017
Change:	-0.55 ▼ (-1.321%)
Day Range	41.00 - 42.05
52-Week Range	17.10 - 47.35
Volume	110,289

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Foundation Medicine is a commercial-stage company focused on fundamentally changing the way patients with cancer are treated. Our proprietary molecular information platform generates actionable genomic information about a patient's individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively. The Company's first clinical product, [FoundationOne™](#), is the only commercially available comprehensive molecular infor... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- October 16, 2017*
[Foundation Medicine to Present Validation for FoundationOne CDx™, a Comprehensive Genomic Profiling Assay for Advancing Precision Cancer Care](#)
- October 12, 2017*
[Foundation Medicine Announces Timing for Third Quarter 2017 Financial Results and Conference Call](#)
- October 10, 2017*
[Foundation Medicine Appoints Tom Civik as Chief Commercial Officer](#)
- October 2, 2017*
[Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay](#)
- September 8, 2017*
[Foundation Medicine to Present Validation Data for Its Assay Measuring Tumor Mutational Burden in Blood \(bTMB\), a New, Non-Invasive Predictor of Response to Immunotherapy](#)

Upcoming Events [\[View all \]](#)

- November 1, 2017 4:30 PM ET*
[Foundation Medicine Third Quarter 2017 Financial Results Conference Call](#)
- Nov 16–19, 2017*
[AONN – Academy of Oncology Nurse & Patient Navigators](#)
- Second Quarter Financial Results*
- March 3, 2017*
[Annual Report \(10-K\)](#)
- April 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- August 1, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- November 2, 2016*
[Quarterly Report \(10-Q\)](#)